MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel therapeutic and prophylactic vaccines, announced that its prophylactic vaccine against coccidioidomycosis, also known as San Joaquin Valley Fever (SJVF), demonstrated statistically significant proof-of-concept results in an animal (murine, n=39) model assay. The animal model data demonstrated the low-dose efficacy of MycoLogics’ proprietary prophylactic [...]